Literature DB >> 32257774

Coronavirus Disease-19: The First 7,755 Cases in the Republic of Korea.

.   

Abstract

We report the first 7,755 patients with confirmed COVID-19 in Korea as of March 12th, 2020. A total of 66 deaths have been recorded, giving a case fatality proportion of 0.9%. Older people, and those with comorbidities were at a higher risk of a fatal outcome. The highest number of cases of COVID-19 were in Daegu, followed by Gyeongbuk. This summary may help to understand the disease dynamics in the early phase of the COVID-19 outbreaks, and may therefore, guide future public health measures.
Copyright ©2020, Korea Centers for Disease Control and Prevention.

Entities:  

Keywords:  COVID-19; SARS-CoV-2; epidemiology

Year:  2020        PMID: 32257774      PMCID: PMC7104685          DOI: 10.24171/j.phrp.2020.11.2.05

Source DB:  PubMed          Journal:  Osong Public Health Res Perspect        ISSN: 2210-9099


Introduction

Only a few weeks after the first case of coronavirus disease 2019 (COVID-19) was reported in Wuhan, China, the first case of COVID-19 was confirmed in the Republic of Korea on January 20th, 2020 [1]. International travel has facilitated the spread of COVID-19 throughout the world. As of March 13th, 2020, 118 countries, territories, and areas have reported COVID-19 cases, however, differences in patterns and intensity of transmission ranges were observed [2]. In February and early March in Korea, a sharp increase in the number of COVID-19 cases were observed, with most infections in specific clusters and geographical regions. Based on the surveillance data, we report the basic epidemiological characteristics of COVID-19 to examine the early course of the pandemic. Furthermore, factors associated with COVID-19 cases and fatality were investigated to provide information on a vulnerable part of the population to guide public health prioritization.

Materials and Methods

This is a summary of the first 7,755 patients with confirmed COVID-19 in Korea as of March 12th, 2020. To obtain demographic, epidemiological, and early clinical information, COVID-19 reporting and surveillance data were retrieved from Korea Centers for Disease Control and Prevention (KCDC)-operated National Notifiable Disease Surveillance System (NNDSS) [3]. The patient age was provided on the date of diagnosis, and key indicators such as estimated duration of exposure, date of onset of symptoms, and route of transmission were identified by field epidemiological investigators [1]. It must be noted that the data presented in this summary may change depending on the results of further epidemiological investigations.

Results

As of March 12th, 2020, a total of 7,755 laboratory-confirmed cases of COVID-19 and 66 deaths were recorded in Korea, giving a case fatality proportion of 0.9% (Table 1). The female-to-male ratio of confirmed COVID-19 cases was 62:38. The age group 20–29 years accounted for the highest level of all confirmed cases at 28.9%, followed by 50–59 years, and 40–49 years. The case fatality proportion was 0.1% among 30–39 years and 40–49 years age groups, then increased to 0.4% in the 50–59 years, 1.5% in the 60–69 years, 5.0% in the 70–79 years, and 8.5% in the ≥80 years age groups (Table 1).
Table 1

Demographics and case fatality proportion of the first 7,755 laboratory-confirmed COVID-19 cases, as of March 12th 2020, Republic of Korea.

VariablesConfirmed casesDeathsCFP



n%n%
Sex
 Female4,808(62.0)25(0.5)
 Male2,947(38.0)35(1.2)

Age group (y)
 0–975(1.0)--
 10–19405(5.2)--
 20–292,238(28.9)--
 30–39804(10.4)1(0.1)
 40–491,082(14.0)1(0.1)
 50–591,472(19.0)6(0.4)
 60–69960(12.4)14(1.5)
 70–79483(6.2)24(5.0)
 ≥ 80236(3.0)20(8.5)

Total7,75566(0.9)

CFP = case fatality proportion.

The epidemic curves presented in Figures 1 and 2 were generated using National Notifiable Disease Surveillance System (NNDSS) data. Epidemic curves by date of onset preceded epidemic curves by date of diagnosis, by a few days or a week (Figure 1). It must be noted that the date of symptom onset may change depending on further epidemiological investigation, and delayed reporting of cases. Figure 2 depicts an epidemic curve by different regions of Korea: the nationwide, Daegu, Gyeongbuk, and others (outside Daegu and Gyeongbuk). From mid-February, an increased number of cases were reported with a peak in late February and early March. Figure 3 shows the age distribution and sex ratio among Daegu, Gyeongbuk, and others regions. Note the increased proportion of cases in 20–29 years and in females among cases in Daegu and Gyeongbuk.
Figure 1

Epidemic curve of laboratory-confirmed coronavirus disease-19 by date of symptom onset and by date of diagnosis, as of March 7, 2020, Republic of Korea.

Provisional data for date of symptom onset.

Figure 2

Epidemic curve of laboratory-confirmed coronavirus disease-19 cases by date of symptom onset, as of March 7, 2020, Republic of Korea.

Provisional data for date of symptom onset.

Figure 3

Age distribution and sex ratio of the first 7,755 cases of laboratory-confirmed coronavirus disease-19, as of March 12 2020, Republic of Korea.

Fatal cases of COVID-19 in Korea, as of March 12th, 2020 are shown in Tables 2 and 3. Case fatality proportion was the highest among people aged ≥ 80 years in Daegu, followed by those aged 70–79 years in Daegu, and elderly persons ≥ 80 years old in Gyeongbuk. Overall case fatality proportion in Daegu and Gyeongbuk were 0.8% and 1.4%, which were higher than that in other regions with 0.4%. Figure 4 depicts age-specific epidemic curve stratified as 0–59 years and ≥ 60 years. The outbreak generally began with the younger age group, followed by the elderly population.
Table 2

Number of deaths and case fatality proportion for laboratory-confirmed COVID-19 cases by geographic region, as of March 12th 2020, Republic of Korea.

Age group (y)DaeguGyeongbukOthers



DeathsTotal casesCFPDeathsTotal casesCFPDeathsTotal casesCFP
0–9-48--9--18-

10–19-314--43--48-

20–29-1,787--279--173-

30–39-590--76-1137(0.7)

40–49-778-1142(0.7)-162-

50–5911,061(0.1)4260(1.5)1150(0.7)

60–6910719(1.4)4162(2.5)-79-

70–7921373(5.6)369(4.3)-42-

≥ 8015124(12.1)496(4.2)116(6.3)

Total475,794(0.8)161,136(1.4)3825(0.4)

CFP = case fatality proportion.

Table 3

Fatal cases (n = 66) of laboratory-confirmed COVID -19 cases, as of March 12th 2020, Republic of Korea.

Variablesn(%)
Age (y), median (range)77(35–93)

Sex
 Female29(43.9)
 Male37(56.1)

Coexisting condition*
 Any61(96.8)
  Cerebrovascular disease5(7.9)
  Heart disease10(15.9)
  Pulmonary disease11(17.5)
  Kidney disease5(7.9)
  Diabetes23(36.5)
  Hypertension30(47.6)
  Cancer7(11.1)
  Neurodegenerative disorder16(25.4)
 Under investigation5(6.5)

Region
 Daegu47(71.2)
 Gyeongbuk16(24.2)
 Others3(4.5)

Death while in home5(7.6)
Diagnosis after death11(16.7)
Interval, days, median (range)
 Symptom → Death10(1–24)
 Symptom → Diagnosis4(0–20)
 Symptom → Hospitalization4.5(0–11)
 Hospitalization → Death5(0–16)
 Total66

A single case may have multiple comorbidities (investigation files required).

Figure 4

Age-specific epidemic curve of laboratory-confirmed coronavirus disease-19 cases by date of symptom onset, as of March 7, 2020, Republic of Korea.

Provisional data for date of symptom onset.

There were 66 laboratory-confirmed fatal cases of COVID-19, as of March 12th, 2020 (Table 3). The median age was 77 years (range, 35–93 years), and female-to-male ratio of 44:56. Of 63 cases, 96.8% were reported to have comorbidities: 47.6% hypertension, 36.5% diabetes, 16% neurodegenerative disorders, and 17.5% pulmonary diseases. There were 71.2% of fatal cases in Daegu and 24.2% were from Gyeongbuk. There were 5 patients who succumbed to death at home, and COVID-19 was identified as the cause of death in 11 individuals after their death. The median interval between onset of symptoms and death was 10 days (range 1–24 days), while the median interval between date of hospitalization and date of death was 5 days (range 0–16 days).

Discussion

The analysis of the first 7,755 cases of COVID-19 in Korea showed an initial increase in cases in specific geographical regions, comparable to the epidemiological situation in China and Italy [4,5]. In Korea, despite a sharp decline in the number of confirmed cases reported, there were still a relevant number of confirmed cases per week in late February and early March. With descriptive analysis of interim surveillance data, the data suggest that the patient outcome differed markedly between the geographic regions, highlighting the magnitude of surge of cases and access to hospitalization. The difference in age distribution of COVID-19 cases compared with China may reflect active surveillance of a cluster of religious groups tied to the outbreak. A summary of the epidemiological characteristics of the first 7,755 COVID-19 cases in Korea confirms the contagiousness of COVID-19 that led to a nationwide outbreak in a few weeks. Triaging patients for hospitalization, social distancing (to reduce the number of contacts), and reporting the outbreak amongst vulnerable people in the population may have played a role in the recent decline in cases of COVID-19. However, in the initial response to COVID-19, quarantine, early detection, and isolation of suspected cases of COVID-19, may have contributed to lowering the wave of this epidemic in other parts of Korea. More severe cases were reported in the elderly with existing comorbidities, which warrants clear triage management and a high-risk approach in healthcare access prioritization. COVID-19 does not appear to be fatal among young adults and children, however their role in disease transmission should be further assessed. This summary may help in the understanding of early phase disease dynamics for the COVID-19 outbreak, and guide future public health measures in other countries.
  4 in total

1.  National Infectious Diseases Surveillance data of South Korea.

Authors:  Sunhee Park; Eunhee Cho
Journal:  Epidemiol Health       Date:  2014-11-11

2.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China.

Authors:  Chaolin Huang; Yeming Wang; Xingwang Li; Lili Ren; Jianping Zhao; Yi Hu; Li Zhang; Guohui Fan; Jiuyang Xu; Xiaoying Gu; Zhenshun Cheng; Ting Yu; Jiaan Xia; Yuan Wei; Wenjuan Wu; Xuelei Xie; Wen Yin; Hui Li; Min Liu; Yan Xiao; Hong Gao; Li Guo; Jungang Xie; Guangfa Wang; Rongmeng Jiang; Zhancheng Gao; Qi Jin; Jianwei Wang; Bin Cao
Journal:  Lancet       Date:  2020-01-24       Impact factor: 79.321

3.  First cases of coronavirus disease 2019 (COVID-19) in the WHO European Region, 24 January to 21 February 2020.

Authors:  Gianfranco Spiteri; James Fielding; Michaela Diercke; Christine Campese; Vincent Enouf; Alexandre Gaymard; Antonino Bella; Paola Sognamiglio; Maria José Sierra Moros; Antonio Nicolau Riutort; Yulia V Demina; Romain Mahieu; Markku Broas; Malin Bengnér; Silke Buda; Julia Schilling; Laurent Filleul; Agnès Lepoutre; Christine Saura; Alexandra Mailles; Daniel Levy-Bruhl; Bruno Coignard; Sibylle Bernard-Stoecklin; Sylvie Behillil; Sylvie van der Werf; Martine Valette; Bruno Lina; Flavia Riccardo; Emanuele Nicastri; Inmaculada Casas; Amparo Larrauri; Magdalena Salom Castell; Francisco Pozo; Rinat A Maksyutov; Charlotte Martin; Marc Van Ranst; Nathalie Bossuyt; Lotta Siira; Jussi Sane; Karin Tegmark-Wisell; Maria Palmérus; Eeva K Broberg; Julien Beauté; Pernille Jorgensen; Nick Bundle; Dmitriy Pereyaslov; Cornelia Adlhoch; Jukka Pukkila; Richard Pebody; Sonja Olsen; Bruno Christian Ciancio
Journal:  Euro Surveill       Date:  2020-03

4.  Early Epidemiological and Clinical Characteristics of 28 Cases of Coronavirus Disease in South Korea.

Authors: 
Journal:  Osong Public Health Res Perspect       Date:  2020-02
  4 in total
  52 in total

1.  Coronavirus disease 2019 in children: Surprising findings in the midst of a global pandemic.

Authors:  Ran D Goldman
Journal:  Can Fam Physician       Date:  2020-05       Impact factor: 3.275

2.  Clinical Features and Outcomes of Coronavirus Disease 2019 Among People With Human Immunodeficiency Virus in the United States: A Multicenter Study From a Large Global Health Research Network (TriNetX).

Authors:  George A Yendewa; Jaime Abraham Perez; Kayla Schlick; Heather Tribout; Grace A McComsey
Journal:  Open Forum Infect Dis       Date:  2021-06-01       Impact factor: 3.835

3.  Prevalence of comorbidities in patients and mortality cases affected by SARS-CoV2: a systematic review and meta-analysis.

Authors:  Omar Ariel Espinosa; Andernice Dos Santos Zanetti; Ednardo Fornanciari Antunes; Fabiana Gulin Longhi; Tatiane Amorim de Matos; Paula Franciene Battaglini
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2020-06-22       Impact factor: 1.846

Review 4.  The role of children in transmission of SARS-CoV-2: A rapid review.

Authors:  Xue Li; Wei Xu; Marshall Dozier; Yazhou He; Amir Kirolos; Evropi Theodoratou
Journal:  J Glob Health       Date:  2020-06       Impact factor: 4.413

Review 5.  Coronavirus Disease 2019 and Diabetes: The Epidemic and the Korean Diabetes Association Perspective.

Authors:  Junghyun Noh; Hyun Ha Chang; In Kyung Jeong; Kun Ho Yoon
Journal:  Diabetes Metab J       Date:  2020-06       Impact factor: 5.376

6.  SARS-CoV-2 Seroprevalence and Neutralizing Antibody Response after the First and Second COVID-19 Pandemic Wave in Croatia.

Authors:  Tatjana Vilibic-Cavlek; Vladimir Stevanovic; Maja Ilic; Ljubo Barbic; Krunoslav Capak; Irena Tabain; Jasna Lenicek Krleza; Thomas Ferenc; Zeljka Hruskar; Renata Zrinski Topic; Vanja Kaliterna; Arlen Antolovic-Pozgain; Jasmina Kucinar; Iva Koscak; Dijana Mayer; Mario Sviben; Ljiljana Antolasic; Ljiljana Milasincic; Lovro Bucic; Ivana Ferencak; Bernard Kaic
Journal:  Pathogens       Date:  2021-06-20

Review 7.  Epidemiology, clinical spectrum, viral kinetics and impact of COVID-19 in the Asia-Pacific region.

Authors:  Kin On Kwok; Ying Huang; Margaret Ting Fong Tsoi; Arthur Tang; Samuel Yeung Shan Wong; Wan In Wei; David Shu Cheong Hui
Journal:  Respirology       Date:  2021-03-09       Impact factor: 6.424

Review 8.  COVID-19 breakthroughs: separating fact from fiction.

Authors:  Paraminder Dhillon; Manuel Breuer; Natasha Hirst
Journal:  FEBS J       Date:  2020-07-05       Impact factor: 5.622

Review 9.  Encountering COVID-19 as Endocrinologists.

Authors:  Eun Jung Rhee; Jung Hee Kim; Sun Joon Moon; Won Young Lee
Journal:  Endocrinol Metab (Seoul)       Date:  2020-04-23

10.  SARS-CoV-2 testing and outcomes in the first 30 days after the first case of COVID-19 at an Australian children's hospital.

Authors:  Laila F Ibrahim; Shidan Tosif; Sarah McNab; Samantha Hall; Hyun Jung Lee; Stuart Lewena; Andrew J Daley; Nigel W Crawford; Andrew C Steer; Penelope A Bryant; Franz E Babl
Journal:  Emerg Med Australas       Date:  2020-06-23       Impact factor: 2.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.